Itziar de Aguirre

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rafael Rosell, Miguel Angel Molina, Carlota Costa et al. · Clinical Cancer Research · 2011 · 300 citations · Full text

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 234 citations · Full text

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Imane Chaib, Niki Karachaliou, Sara Pilotto et al. · JNCI Journal of the National Cancer Institute · 2017 · 216 citations · Full text

Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients

José Luis Ramírez, Carme Sarries, Pedro López de Castro et al. · Cancer Letters · 2003 · 117 citations

Oncology, Somatic Variant, Oncogenic Agent +12